Breaking News
Get 45% Off 0
🎯 Trump Tariffs Hit Markets: Here's What Smart Investors Should Consider
Read now

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
S&P Begins July With Sixth Straight Record Close By Zacks Investment Research - Jul 01, 2021

The market just kicked off a whole new quarter and half on Thursday, but the action (or lack thereof) is anything but new. And that’s all right! It means that stocks continue to grind upward...

2 Tech Stocks to Buy in Q3 and Hold for Years By Zacks Investment Research - Jul 01, 2021

The S&P 500 hit new records on the final day of the second quarter. The benchmark index has climbed over 14% in the first half of 2021 and is up roughly 27% from its pre-pandemic levels in...

Can the Rally in Smith & Wesson (SWBI) Shares Continue? By Zacks Investment Research - Jul 01, 2021

As of late, it has definitely been a great time to be an investor of Smith & Wesson Brands, Inc. SWBI. The stock has moved higher by nearly 59% in the past month, while it is also above its 20 Day...

You Have a Theory, Which Options Should You Choose? By Zacks Investment Research - Jul 01, 2021

Options contracts have been around for hundreds or possibly even thousands of years, but the modern exchange-traded, standardized options have only been in existence since 1973.Starting with calls -...

Should You Buy Steel Stocks Now? By Zacks Investment Research - Jul 01, 2021

Since the beginning of the year, the steel industry has done remarkably well, making it one of the hottest segments of the materials sector. But as we enter the second half of the year, one question...

Vanda (VNDA) Moves 5.8% Higher: Will This Strength Last? By Zacks Investment Research - Jul 01, 2021

Vanda (NASDAQ:VNDA) Pharmaceuticals (VNDA) shares soared 5.8% in the last trading session to close at $21.51. The move was backed by solid volume with far more shares changing hands than in a normal...

Top ETF Stories of 1H 2021 & 2H Outlook By Zacks Investment Research - Jul 01, 2021

(1:00) - Equity ETFs Massive Growth(8:50) - Cathie Wood’s Ark Invest Files For Bitcoin ETF(15:20) - ARK Invest’s ETFs Rally(19:30) - Top New ETFs of 2021(27:05) - Episode Roundup:...

Saratoga Investment (SAR) Reports Next Week: What to Expect By Zacks Investment Research - Jul 01, 2021

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Saratoga Investment (NYSE:SAR) reports results for the quarter ended May 2021. While this widely-known...

ETFs to Play the Impressive Wall Street Rally in 1H21 By Zacks Investment Research - Jul 01, 2021

Wall Street has impressed investors in the first half of 2021, with major indices like the S&P 500 rising 14.4%, while the Nasdaq Composite and the Dow Jones Industrial Average have each climbed...

Transportation Stocks Reviving Dividend Hikes: 3 Solid Picks By Zacks Investment Research - Jul 01, 2021

It is no secret that stocks in the widely-diversified transportation sector were one of the worst hit last year due to the coronavirus pandemic. With revenue stream dwindling, companies belonging to...

Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze By Zacks Investment Research - Jun 30, 2021

Jazz Pharmaceuticals (NASDAQ:JAZZ) plc JAZZ announced that the FDA has granted approval to a biologics license application (BLA) seeking approval of its novel asparaginase, Rylaze (JZP-458). The drug...

Continue with Apple
Continue with Google
or
Sign up with Email